Update on FDG-PET in pediatric lymphoma
Q J Nucl Med Mol Imaging. 2024 Mar;68(1):58-69. doi: 10.23736/S1824-4785.24.03560-X.ABSTRACTLymphoma represent the third most common malignant disease in childhood and adolescence. They are divided into pediatric Hodgkin lymphoma (P-HL) and pediatric non-Hodgkin lymphoma (P-NHL). In P-HL, excellent cure rates are achieved through combined modality treatment using chemotherapy and radiotherapy. For more than 20 years, FDG-PET has been an integral part of the treatment and guides its intensity through improved staging and precise assessment of chemotherapy response. In P-NHL, good cure rates are achieved with chemotherapy al...
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - April 8, 2024 Category: Nuclear Medicine Authors: Lars Kurch Regine Kluge Source Type: research
Update on FDG-PET in pediatric lymphoma
Q J Nucl Med Mol Imaging. 2024 Mar;68(1):58-69. doi: 10.23736/S1824-4785.24.03560-X.ABSTRACTLymphoma represent the third most common malignant disease in childhood and adolescence. They are divided into pediatric Hodgkin lymphoma (P-HL) and pediatric non-Hodgkin lymphoma (P-NHL). In P-HL, excellent cure rates are achieved through combined modality treatment using chemotherapy and radiotherapy. For more than 20 years, FDG-PET has been an integral part of the treatment and guides its intensity through improved staging and precise assessment of chemotherapy response. In P-NHL, good cure rates are achieved with chemotherapy al...
Source: Molecular Medicine - April 8, 2024 Category: Molecular Biology Authors: Lars Kurch Regine Kluge Source Type: research
Update on FDG-PET in pediatric lymphoma
Q J Nucl Med Mol Imaging. 2024 Mar;68(1):58-69. doi: 10.23736/S1824-4785.24.03560-X.ABSTRACTLymphoma represent the third most common malignant disease in childhood and adolescence. They are divided into pediatric Hodgkin lymphoma (P-HL) and pediatric non-Hodgkin lymphoma (P-NHL). In P-HL, excellent cure rates are achieved through combined modality treatment using chemotherapy and radiotherapy. For more than 20 years, FDG-PET has been an integral part of the treatment and guides its intensity through improved staging and precise assessment of chemotherapy response. In P-NHL, good cure rates are achieved with chemotherapy al...
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - April 8, 2024 Category: Nuclear Medicine Authors: Lars Kurch Regine Kluge Source Type: research
